CORT - CORCEPT THERAPEUTICS INC
IEX Last Trade
52.575
0.350 0.666%
Share volume: 6,434
Last Updated: Fri 27 Dec 2024 06:29:55 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.96%
PREVIOUS CLOSE
CHG
CHG%
$52.22
0.35
0.67%
Fundamental analysis
59%
Profitability
72%
Dept financing
5%
Liquidity
75%
Performance
55%
Performance
5 Days
2.50%
1 Month
-10.94%
3 Months
20.54%
6 Months
65.09%
1 Year
60.92%
2 Year
160.72%
Key data
Stock price
$52.58
DAY RANGE
$51.87 - $53.33
52 WEEK RANGE
$21.76 - $62.22
52 WEEK CHANGE
$58.67
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: Joseph K. Belanoff
Region: US
Website: corcept.com
Employees: 300
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: corcept.com
Employees: 300
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the. treatment of hyperglycemia secondary to hypercortisolism in adult patients with. endogenous Cushing's syndrome.
Recent news